| | 877399-52-5 Basic information More.. |
| Product Name: | Crizotinib | | Synonyms: | (R)-3-[1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H- pyrazol-4-yl)pyridin-2-ylaMine;[3-[[(R)-1-(2,6-Dichloro-3-
fluorophenyl)ethyl]oxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-yl]aMine;2-PyridinaMine, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-;Crozotinib;Crizotinib,PF-02341066;Crizotinib (PF2341066);PF-02341066 Crizotinib;3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine | | CAS: | 877399-52-5 | | MF: | C21H22Cl2FN5O | | MW: | 450.34 | | EINECS: | 638-814-9 | | Mol File: | 877399-52-5.mol |  |
Use
Crizotinib (Xalkori(R), Pfizer), approved in 2011, was the first approved inhibitor targeting anaplastic lymphoma kinase (ALK). ROS protooncogene 1-encoded kinase (ROS1) of the tyrosine kinase insulin receptor class and MET proto-oncogene-encoded kinase of the hepatocyte growth factor receptor (HGFR) class are other kinases targeted by crizotinib.When approved in 2011, crizotinib was the first drug specifically targeting NSCLC patients. However, resistance to crizotinib was usually observed in approximately 8 months after initial application and more than half of crizotinib-treated patients experienced gastrointestinal side effects. In 2016,crizotinib was additionally approved for ROS1-positive NSCLC by FDA.
- Crizotinib
-
- 2026-06-07
- CAS:877399-52-5
- Purity: 0.99
- Crizotinib
-
- 2026-06-02
- CAS:877399-52-5
- Min. Order: 1kg
- Purity: 0.99
- Supply Ability: 1000kg
- Crizotinib
-
- $44.00
- 2026-05-26
- CAS:877399-52-5
- Purity: 99.76%
- Supply Ability: 10g
|
|
877399-52-5
Recommend Suppliers |
|